Boston Scientific (NYSE: [[ticker:BSX]]) said today it scored a victory with a U.S. District Court in Texas. A jury had previously determined the Natick, MA-based medical device company violated Medtronic’s patents on balloon catheters and stent delivery systems, awarding damages of $250 million. The court today found that two patents held by Medtronic (NYSE: [[ticker:MDT]]) were unenforceable, and it chose to reduce damages awarded to $19 million. Boston Scientific plans to appeal the remaining $19 million damage award to the U.S. Court of Appeals in Washington, and said it is “confident” it will win.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
